Interleukin-10 (IL-10) in Cancer Immunotherapy

Abstract

Cancer immunotherapy is an essential therapeutic strategy for the treatment of cancer. In cancer immunotherapy, cytokines, such as interleukin-10 (IL-10), have a vital function. IL-10, synthesized by several types of immune cells, has a vital function in controlling immunological responses, such as subsistence T cells and dendritic cells (DCs), as well as other kinds of cells producing other cytokines. In the immune system, suppressing or reducing the growth and harmful effects of specific immune cells is the main role of this component. Pegylated recombinant human IL-10 and other IL-10 inhibitors can reverse the suppressive impact of IL-10, providing possible ways to control immune responses. IL-10 is mainly recognized for its ability to reduce inflammation and regulate the immune system. However, its involvement in cancer is complex and varies depending on the specific circumstances. IL-10-based treatment has had some degree of success in several forms of cancer. Furthermore, IL-10-derived medications have achieved significant advancements in both animal models and clinical studies, including in humans. While the rate of research progress may fluctuate for various types of malignancies, existing records suggest that IL-10-based immunotherapy shows promising potential.